Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Interim Advice on the use of Rifampicin for post-exposure prophylaxis (PEP), in light of recent information on nitrosamine impurities in rifampicin

ILEP Technical Commission . 2021;
Download PDF
Publication

Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience.

Lastória J, Putinatti M, de Almeida T, et al. Anais brasileiros de dermatologia. 2018; 93 (2) : 181-184.
Download PDF
Publication

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.

Cruz R, Bührer-Sékula S, Penna GO, et al. Anais brasileiros de dermatologia. 2018; 93 (3) : 377-384.
Download PDF
Publication

A comprehensive research agenda for zero leprosy

Steinmann P, Dusenbury C, Addiss D, et al. Springer Science and Business Media LLC. Infectious Diseases of Poverty. 2020;
Download PDF
Publication

Dapsone-induced optic atrophy: a rare case report

Shrestha S, Chaudhary S, Giri H, et al. Lepra. Leprosy Review. 2020; 91 (3) : 291-294.
Download PDF
Publication

The adverse drug effects of dapsone therapy in leprosy: a systematic review

Hilder R, Lockwood D. Lepra. Leprosy review. 2020; 91 (3) : 232-243.
Download PDF
Publication

Functional Outcome of Early, Selective Surgical Nerve Decompression in Leprous Neuropathy.

Khan Y, Prakash S, Kalra P, et al. The journal of hand surgery Asian-Pacific volume. 2020; 25 (4) : 407-416.
Publication

Evaluation of National Leprosy Eradication Programme in Pune city of Maharashtra from 2008 to 2019 – A Record Based Study

Anand V, Kunte R, Jathar S, et al. Indian journal of leprosy. 2020;
Download PDF
Publication

Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.

Krismawati H, Irwanto A, Pongtiku A, et al. PLoS neglected tropical diseases. 2020; 14 (10) : e0008746.
Download PDF
Publication

Analysis of bacteriological Index between fixed multidrug therapy and new WHO recommended alternative regimen with ofloxacin, minocycline and clofazimine of rifampicin resistant cases from the hospitals of The Leprosy Mission, India.

Lavania M, Darlong J, Singh I, et al. Journal of global antimicrobial resistance. 2020;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 27
  • Next page ››
Subscribe to Multi-drug therapy (MDT)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

  • infontd

© 2025 InfoNTD